Preclinical assessments of the MEK inhibitor PD‐0325901 in a mouse model of Neurofibromatosis type 1

Publisher： John Wiley & Sons Inc

E-ISSN： 1545-5017|62|10|1709-1716

ISSN： 1545-5009

Source： PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol.62, Iss.10, 2015-10, pp. : 1709-1716

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Characterization of early communicative behavior in mouse models of neurofibromatosis type 1

By  

AUTISM RESEARCH (ELECTRONIC), Vol. 11, Iss. 1, 2018-01 ,pp. : 44-58

John Wiley & Sons Inc

Access to resources Recommend Favorite

An extreme case of neurofibromatosis type 1

By Štimac Davor   Novak Srdjan   Guina Tina  

Wiener klinische Wochenschrift, Vol. 119, Iss. 3-4, 2007-03 ,pp. : 90-90

Springer Publishing Company

Access to resources Recommend Favorite

Efficacy of the MEK inhibitor cobimetinib for wild‐type BRAF Erdheim‐Chester disease

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 180, Iss. 1, 2018-01 ,pp. : 150-153

John Wiley & Sons Inc

Access to resources Recommend Favorite

Ganglioglioma of the Spinal Cord in Neurofibromatosis Type 1

By  

Pediatric Neurosurgery, Vol. 49, Iss. 1, 2013-10 ,pp. : 50-54

Karger

Access to resources Recommend Favorite

Muscle weakness in children with neurofibromatosis type 1

By  

DEVELOPMENTAL MEDICINE & CHILD NEUROLOGY, Vol. 57, Iss. 8, 2015-08 ,pp. : 733-736

John Wiley & Sons Inc

Access to resources Recommend Favorite